SCHEMBL6487322

SCHEMBL6487322

Cc1ccc(-c2ccc(C(=O)N[C@@H]3C[C@@H]4CCN(C4)C3)o2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 7/20 0.50
ALDH1A1 P00352 4/20 0.50
MAPT P10636 3/20 0.50
KMT2A Q03164 3/20 0.50
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 1/20 0.48
MMP13 P45452 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPK11 Q15759 1/20 0.42
MAPK14 Q16539 1/20 0.42
MGAM O43451 1/20 0.42
SI P14410 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487314 1.00 CHRNA7 (0.50) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6490510 0.90 CHRNA7 (0.51) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6490515 0.90 CHRNA7 (0.51) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6488042 0.89 MMP13 (0.49) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6488035 0.89 MMP13 (0.49) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6487083 0.89 CHRNA7 (0.50) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6497302 0.89 CHRNA7 (0.65) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6500084 0.89 CHRNA7 (0.50) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6487071 0.89 CHRNA7 (0.50) CHRNA7ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6497296 0.89 CHRNA7 (0.65) CHRNA7ALDH1A1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 CHRNA7 1097/4885ALDH1A1 625/4885MAPT 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.